Abstract: According to one general aspect, a method may include receiving a virtual data field definition from a user interface model. The virtual data field may include a data field does not have a counterpart in a database of actual data fields. The method may include dynamically generating the virtual data field based upon the virtual data field definition. The method may include responding to a data request from the user interface with a plurality of data fields, wherein the plurality of data fields include both the virtual data field and an actual data field included by the database.

Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.

Abstract: A system and method for modeling properties of data and events of a business application is presented. The system include a user interface frontend system that displays a user interface, and a user interface backend system that hosts a business application that generates the user interface for display in the user interface frontend system. The system further includes an enterprise service framework comprising one or more data processors that define one or more properties of data and/or events related to the business application, and model each of the one or more properties as a data field of the business application. A dynamic properties calculator includes one or more data processors that access a set of transformation logic representing data transformation rules for each of the data fields of the business application, and apply the transformation rules to the data fields that represent the one or more properties.

Abstract: The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system.

Abstract: The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide.

Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.

Abstract: The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers.

Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.

Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.

Abstract: New bifunctional chelation complexes are described. These are based on the structure of the so-called “TAME-HexA” molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes.

Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.

Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.

Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.

Abstract: The subject matter disclosed herein provides methods and apparatus, including computer program products, for logging and evaluating activity to support optimizing and streamlining a process, such as a business process. In one aspect, there is provided a computer-implemented method. The method include receiving information representative of activity at a user interface. The received information may be aggregated to form aggregated data. The received information may be evaluated to determine one or more proposals. The evaluation may use the context of a task being performed at the user interface and the activity at the user interface. The one or more proposals may be provided to enable a configuration of a system or a business process with at least one of the proposals. Related apparatus, systems, methods, and articles are also described.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or o

Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.